Point Roberts, WA - March 29, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, reports on advances in Cancer Immunotherapy. Bristol-Myers Squibb Company (NYSE:BMY) announced Friday that the U.S. Food and Drug Administration (FDA) approved YERVOY (ipilimumab) 3 mg/kg for the treatment of patients with unresectable (inoperable) or metastatic melanoma.
Bristol-Myers Squibb Company (NYSE:BMY) hit a 52 week high on Friday.
"The approval of YERVOY illustrates the power of harnessing the patient's own immune system to combat cancer,” stated Jim Joyce, CEO of Aethlon Medical. "With the recent approval of PROVENGE from Dendreon, the cancer immunotherapy era seems to be well underway.
- Published: 29 March 2011
- Written by Investor Ideas